Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. Nuclear & Precision Health Solutions has 40+ years of expertise and is a national source for both SPECT and PET radiopharmaceuticals, operating the largest network of 130 pharmacies, 30+ cyclotron facilities, and the only Alpha contract manufacturing site in the United States.
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis, pharmaco-imaging & artificial intelligence, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in imaging and targeted radiotherapies.
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal imaging platforms are an open door for non-invasive techniques to understand the pharmacology of your compound in less than 6 months. Finally, we have a unique offering dedicated to pre-clinical evaluation of TRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess systemic radiotherapy efficacy.
ABX-CRO is an independent international CRO with more than 20 years of experience in radiooncology, dosimetry, and molecular radiotherapy. ABX-CRO offers product development services from non-clinical through Phase-0 microdosing to global Phase III studies. Highly specialised radiooncology trials require close multidisciplinary interaction of pharmacists, physicists, clinicians and statisticians, as well as clinical trial experts all the way through from study design and conduct to final statistical analysis. Reflecting this, ABX-CRO comprehensively integrates scientific, medical and clinical trial management expertise required for advanced imaging and therapeutic trials. We closely cooperate with key opinion leaders, research institutes and universities worldwide to realise non-clinical studies for novel IMPs and to ensure recruitment and adequate treatment facilities for a wide range of indications.
Located near Aix-en-Provence, in France, PMB is a 160-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency…), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.
PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room. Our GMP-compliant R&D iMiLAB synthesizer allows the development of various radiopharmaceuticals using microfluidic cassettes. It can also be used for the production of single doses or small batches.
FIELD-LAB - NRG
Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.